PATENT CLAIM ANALYSIS

Application Number: 16148749
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "001000"]

Abstract:
The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvent thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), or emerging cirrhosis.

Claim (Index 16):
The method of  claim 15 , wherein the one or more additional active agents are one or more antiretroviral agents selected from the group consisting of entry inhibitors, nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, maturation inhibitors, and combinations thereof.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 97.0
- Lexical Diversity: 1.63043
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15612124', '15979881', '15460917', '16133322', '16006615']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7266088843957839
- 35 USC 102 Novelty (BERT): 0.5308364769996274
- Combined Prediction Score: 0.7070316436561682
- Mean Citation Score: 275.954396
- Max Citation Score: 321.28372
- Similarity Product: 201.6968598935508

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test